The Risk of GLP-1 on Chick-Fil-A

The fast-food industry is changing as consumer preferences evolve, partly due to the rising use of GLP-1 weight loss drugs, which suppress appetite and encourage smaller portions. As more people turn to these medications, chains like Chick-Fil-A must reconsider their menus and sales strategies. Chick-Fil-A, known for its high-quality chicken offerings and customer loyalty, is well positioned to respond — though the long-term impact pf GLP-1 on consumer behavior remains uncertain.

GLP-1 drugs mimic a hormone 1 that reduces appetite and slows digestion, lowering calorie intake 2. Users often shift toward healthier foods like lean proteins, fruits, and vegetables, while avoiding processed, high-calorie, or high-fat foods.

Although about 12% of US adults have tried GLP-1 drugs 3, adherence remains low. Only 27% of users take the medication consistently 4. 30% stopped taking them within four weeks 5, 54% within 1 year, and 72% within 2 years 6. Even those who continue taking the drug sometimes pause usage, primarily to enjoy food without side effects 7. These trends suggest that while GLP-1 drugs influence food choices, its long-term impact may be limited.

As GLP-1 reshapes consumer eating habits, Chick-Fil-A faces both challenges and opportunities. One advantage is that GLP-1 users prefer chicken over red meat. Additionally, Chick-Fil-A leads with the highest percentage of GLP-1 users, with 68% of users favoring the chain 8 – likely due to its healthier menu and strong service reputation and cleanliness. Although dining out is declining among GLP-1 users, fast food remains their top choice for eating out likely due to its conveniency, with 59% of GLP-1 users still interested in value menu items 8. Chick-Fil-A's customer base — young adults, middle-class families, health-conscious consumers, and urban/suburban residents 9 — tend to have lower obesity rates and are thus less likely to use the drug. Sales in combo meals, fried foods, desserts, and sugary drinks may decline, while interest in lighter, high-protein options may grow.

Although GLP-1 doesn’t currently pose a major risk, Chick-Fil-A can still adapt to changing consumer preferences by highlighting healthy items and keeping classics. Customizable portion sizes and snack packs can appeal to both GLP-1 users and light eaters. Adding smart options like a grilled chicken and avocado bowl, sugar-free sauces, and protein or veggie swaps can enhance flexibility. Using inclusive language like “Smart Choices” instead of “GLP-1 friendly” broadens appeal. These enhancements will help the brand evolve while satisfying a diverse customer base.

While GLP-1 drugs are influencing food habits, their long-term impact on fast food remains uncertain. Chick-Fil-A is well positioned to adapt, given its strong consumer base, specialty in chicken, healthier menu options, and large menu variety. By balancing core offerings with strategic updates, they can serve both traditional and health-conscious customers. Chick-Fil-A’s success will depend on how well it tracks and responds to these emerging trends.

Citations

1. Cleveland Clinic. GLP-1 agonists. Cleveland Clinic. March 19, 2025. Accessed April 4, 2025. https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists.

2. Aldawsari M, Almadani FA, Almuhammadi N, Algabsani S, Alamro Y, Aldhwayan M. The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: Systematic review of Randomized Controlled Trials. *Diabetes, Metabolic Syndrome and Obesity*. 2023;Volume 16:575-595. doi:10.2147/dmso.s387116

3. Montero A, Sparks G, Presiado M, Hamel L. KFF Health Tracking Poll May 2024: The public’s use and views of GLP-1 Drugs. KFF. May 10, 2024. Accessed April 2, 2025. https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/.

4. Starr M. Report: GLP-1 adherence rates lower than expected. Pharmacy Practice News. May 23, 2024. Accessed April 2, 2025. https://www.pharmacypracticenews.com/Online-First/Cardiology/Article/05-24/Report-GLP-1-Adherence-Rates-Lower-Than-Expected/73868?utm\_source=chatgpt.com.

5. Cassata C. Many patients stop weight management drugs too soon-here’s why that concerns doctors. Health. August 26, 2024. Accessed April 3, 2025. https://www.health.com/weight-management-glp1-short-term-use-8653655.

6. Bose P. High discontinuation rates of GLP-1 agonists found among patients with obesity. News. February 4, 2025. Accessed April 2, 2025. https://www.news-medical.net/news/20250204/High-discontinuation-rates-of-GLP-1-agonists-found-among-patients-with obesity.aspx#:~:text=It%20was%20noted%20that%20about,similar%20discontinuation%20rates%20were%20recorded.

7. Swartz T. 1 in 6 people plan to skip their weight-loss drugs over the holidays so they can eat more. New York Post. December 12, 2024. Accessed April 3, 2025. https://nypost.com/2024/12/12/health/1-in-6-plan-to-skip-their-weight-loss-drugs-over-the-holidays/?utm\_source=chatgpt.com.

8. Shriber S. Top trends that qsrs should know about GLP-1 customers. CivicScience. September 16, 2024. Accessed April 2, 2025. https://civicscience.com/top-trends-that-qsrs-should-know-about-glp-1-customers/?utm\_source=chatgpt.com.

9. Pereira D. Chick-fil-A target market analysis (2025). Business Model Analyst. December 17, 2024. Accessed April 3, 2025. https://businessmodelanalyst.com/chick-fil-a-target-market/?utm\_source=chatgpt.com.